**The FDA does not review or approve any compounded medications for safety or effectiveness
Some research protocols describe this combination as a pure fat-burning combination
By inhibiting this enzyme, 5-Amino-1MQ preserves nicotinamide for NAD+ synthesis, increasing intracellular NAD+ levels through a mechanism entirely distinct from NAD+ precursor supplementation (NMN, NR)
Important Safety Information Do not use AOD-9604 if you: Have active cancer or malignancy (use only under medical supervision with appropriate monitoring) Are pregnant or breastfeeding (safety data lacking in these populations) Have known allergy to growth hormone fragments or peptide compounds Have severe uncontrolled metabolic or cardiovascular disease without medical supervision Common side effects may include: Injection site reactions (mild redness, swelling, or tenderness), occasional mild headaches during initial use, and transient lightheadedness
The result is a starting point only and does not replace medical screening
The combination of tesamorelin and retatrutide, despite its theoretical appeal, suits a narrow profile of researchers with specific goals and risk tolerance
